Scribeable vs Freed AI:
Considering Freed? Here is a factual look at how Scribeable differs. Freed publishes its pricing — credit where due — so this comparison is about what each subscription includes, and who each company answers to.
120+ clinicians · 2,600+ notes generated — real counters, no composites (scribeable.ai/transparency)
Why Physicians Switch from Freed AI
No permanent free tier — Freed's pricing page lists a 7-day trial, then paid plans from $39/month
Coding (E/M, ICD-10, CPT) sits on the Premier tier ($104-119/month) — not included at $39 or $79, per Freed's own pricing page; HCC risk adjustment is not mentioned at any tier
VC-backed: a $30M Series A led by Sequoia Capital (March 2025) sets the growth expectations Freed answers to
Credit Where Due — Then the Fine Print
Freed does what most competitors won't: it publishes its pricing. Starter is $39/month for up to 40 notes, Core is $79/month for unlimited notes, and Premier is $104-119/month. The fine print is what each price includes — on Freed's own pricing page, coding (E/M, ICD-10, CPT) appears only at the Premier tier, and HCC risk adjustment isn't mentioned at all. Scribeable's Pro tier at $79/month includes the coding engine, the HCC V28 crosswalk, and 240 clinical calculators. Same sticker, different contents.
The Note Is the Floor, Not the Ceiling
Freed's site advertises clinical decision support drawn from "50+ trusted sources." What it does not advertise is deterministic validation — calculators scored in code, not by a model's recollection. Scribeable runs 240 clinical calculators with code-scored validation inside every note, plus MIPS quality measures. If your documentation feeds risk-adjusted revenue or quality reporting, that layer is the difference between a transcript summary and a working clinical document.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Freed raised a $30M Series A led by Sequoia Capital in March 2025 — announced on Freed's own blog. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Same Patient. Same Encounter.
See why physicians say Scribeable notes are “actually usable” — with integrated risk scores, billing codes, and clinical reasoning that typical AI scribes simply don’t generate.
HPI
62 y/o male presents with chest pain for 2 hours. Substernal, pressure-like, radiating to left arm. Associated with diaphoresis and shortness of breath. Pain started while climbing stairs. Patient has history of HTN, DM2, and hyperlipidemia. Takes lisinopril, metformin, and atorvastatin. Denies recent illness or trauma.
Assessment & Plan
*Note examples are illustrative representations based on common AI documentation patterns. “Typical AI Scribe” represents composite characteristics of standard tools and does not depict any specific product. Patient scenarios are entirely fictional. Clinical notes should always be reviewed by a licensed provider.
AI Medical Scribe Note Quality Comparison
Scribeable produces clinically enriched notes with integrated risk calculators (HEART Score, CHA₂DS₂-VASc, Wells PE, PHQ-9, Caprini VTE), automated billing code optimization (E&M levels, HCC/RAF capture, CPT codes), dangerous diagnosis exclusion documentation, evidence-based prescribing citations, CMS compliance for operative reports, HEDIS care gap tracking, and MIPS quality measure documentation. Typical AI scribes produce basic notes without these advanced clinical features.
ED Chest Pain: 62-year-old male presenting with substernal chest pressure, diaphoresis, and exertional dyspnea
HPI: 62 y/o male presents with 2 hours of substernal chest pressure, rated 8/10, radiating to left arm and jaw. Onset during exertion (climbing stairs). Associated with diaphoresis and exertional dyspnea. Pressure-like quality, unrelieved by rest. No pleuritic component, no positional variation, no reproducibility with palpation. Risk factors: HTN (10 years), DM2 (8 years), hyperlipidemia, 30-pack-year smoking history (quit 5 years ago), family history of MI (father at age 58). Current medications: lisinopril 20mg daily, metformin 1000mg BID, atorvastatin 40mg daily. Denies cocaine use, recent immobilization, or prior VTE.
Assessment & Plan: 1. Acute Chest Pain — High-risk presentation HEART Score: 7 (High Risk) - History: moderately suspicious (2), EKG: non-specific ST changes (1), Age: >65 (2), Risk factors: ≥3 (2), Troponin: pending initial (0) - Risk stratification: >12% 6-week MACE event rate → full ACS workup - Serial troponins q3h, 12-lead EKG (initial + repeat at 60 min) - ASA 325mg PO administered, heparin drip per ACS protocol - Cardiology consulted for probable cath lab activation Dangerous Diagnosis Exclusion: - STEMI: No ST elevation on initial EKG — serial monitoring - Aortic dissection: No tearing quality, no pulse differential, no mediastinal widening on CXR - PE: Low pretest probability (Wells PE: 1.5) — no immobilization, no prior VTE, no hemoptysis 2. Hypertension — BP 168/94 on arrival, improved to 142/88 post-NTG - Continue home lisinopril, recheck prior to disposition 3. DM2 — Glucose 186 on arrival - Hold metformin (contrast exposure risk), sliding scale insulin PRN
Cardiology Consult: 71-year-old female with new-onset atrial fibrillation and decompensated heart failure
HPI: 71 y/o female with known HFrEF (EF 35% on TTE 6 months ago), HTN, DM2, and CKD Stage 3a (baseline Cr 1.4), consulted for new-onset atrial fibrillation with RVR. Progressive exertional dyspnea (NYHA II → IV over 2 weeks), 3-pillow orthopnea (new), PND, and 4+ pitting edema to knees bilaterally. Weight gain of 8 lbs over 2 weeks. Triggers explored: dietary indiscretion (holiday meals), medication non-adherence (ran out of furosemide 10 days ago). No prior AF history, no palpitations previously. Denies chest pain, syncope, or presyncope.
Assessment & Plan: Reason for Consult: New-onset atrial fibrillation with RVR in setting of acute decompensated HFrEF. Requesting Service: Internal Medicine (Dr. Patel) 1. New-onset Atrial Fibrillation with RVR CHA₂DS₂-VASc Score: 5 (Female sex, age ≥75, HTN, DM, HF) - Stroke risk: 6.7%/year → strong anticoagulation indication - Rate control: avoid diltiazem (negative inotropy in HFrEF) → amiodarone 150mg IV bolus then 1mg/min × 6h - Anticoagulation: apixaban 5mg BID (preferred over warfarin given age + fall risk) - TEE prior to any cardioversion attempt if AF duration uncertain - HAS-BLED: 2 (HTN, age) — acceptable bleeding risk 2. Acute Decompensated Heart Failure (ADHF) NYHA Functional Class: IV (dyspnea at rest) - IV furosemide 80mg BID (2.5× home oral dose), net negative 1-1.5L/day - Carvedilol held (acute decompensation), restart when euvolemic - Add sacubitril/valsartan when stable (PARADIGM-HF indication: EF ≤40% on ACEi) - BNP trend: 1,840 → monitor for response to diuresis 3. CKD Stage 3a — Cr 1.4 (baseline), monitor with aggressive diuresis - KDIGO risk: moderate — monitor Cr/K daily with diuresis
Operative Note: Right total knee arthroplasty in 68-year-old male with severe tricompartmental osteoarthritis
Operative Note: Preoperative Diagnosis: Right knee severe tricompartmental osteoarthritis (Kellgren-Lawrence Grade IV) Postoperative Diagnosis: Same Procedure: Right total knee arthroplasty Surgeon: Dr. James Morrison (attending — present and scrubbed for entire case) Assistant: Dr. Chen (PGY-4) Anesthesia: Spinal with sedation (Dr. Rivera) Implants: Smith & Nephew Legion CR, Size 5 femoral / Size 4 tibial / 10mm poly insert EBL: 150 mL Tourniquet Time: 62 minutes (pneumatic, 275 mmHg) Specimens: Femoral and tibial bone cuts — to pathology Complications: None Findings: Severe tricompartmental degenerative changes with exposed subchondral bone medially, grade III chondromalacia laterally, intact PCL
Post-Operative Plan: 1. Weight Bearing: WBAT right LE with front-wheeled walker 2. DVT Prophylaxis: Enoxaparin 40mg SQ daily × 14 days + mechanical (SCDs while inpatient) 3. Pain: Multimodal — scheduled acetaminophen 1g Q6h, meloxicam 15mg daily, tramadol 50mg Q6h PRN (max 14 days) 4. Antibiotics: Ancef 2g IV × 24h post-op 5. PT: Initiate POD0 PM — CPM machine, active/passive ROM, gait training 6. Follow-up: 2 weeks (staple removal + wound check), 6 weeks (X-ray + ROM assessment) 7. VTE Risk: Caprini Score 7 (High Risk) — extended pharmacologic prophylaxis indicated
Primary Care: 55-year-old female Medicare Advantage patient with DM2, HTN, depression, and overdue preventive care
HPI: 55 y/o female Medicare Advantage patient presenting for chronic disease management follow-up. Last visit 3 months ago. Diabetes (DM2, 8 years): A1c 8.2% (up from 7.6%), reports adherence but dietary indiscretion during holidays. Home glucose logs show fasting 140-180 range. No hypoglycemic episodes. Denies polyuria, polydipsia, vision changes, or foot numbness. Last diabetic eye exam: 14 months ago (overdue). Last podiatry visit: never. Hypertension (12 years): Home BP readings averaging 135-145/85-90. Taking lisinopril 20mg daily consistently. Depression (MDD, recurrent): PHQ-9 score today: 14 (moderately severe). Persistent low mood, anhedonia, poor sleep (initial insomnia), decreased concentration. On sertraline 50mg × 6 months with partial response. Denies SI/HI, denies alcohol or substance use. Columbia Suicide Severity: negative for ideation and behavior.
Assessment & Plan: 1. DM2, Uncontrolled (A1c 8.2%) — HCC 19 - Add empagliflozin 10mg daily (SGLT2i — CV and renal benefit, EMPA-REG OUTCOME indication) - Continue metformin 500mg BID (not escalating given GI intolerance history) - Diabetic eye exam referral (overdue 2 months — HEDIS measure) - Podiatry referral for initial foot exam - Recheck A1c in 3 months, target <7% 2. Hypertension, Suboptimally Controlled — HCC (when with CKD/DM) - BP today 138/86 — above target of <130/80 (ACC/AHA for DM patients) - Increase lisinopril to 40mg daily - Home BP log review in 4 weeks 3. Major Depressive Disorder, Recurrent, Moderate — HCC 59 - PHQ-9: 14 (moderately severe) — partial response to sertraline 50mg - Increase sertraline to 100mg daily - Safety plan reviewed, crisis line provided (988) - Follow-up in 4 weeks, recheck PHQ-9 - If inadequate response → consider augmentation or psychiatry referral 4. Preventive Care Gaps Addressed: - Mammogram ordered (last: 26 months ago — HEDIS BCS measure) - Colonoscopy referral (age 55, average risk, never screened — HEDIS COL) - Tobacco screening: former smoker, quit 3 years — MIPS measure 226 - Annual flu vaccine administered today — MIPS measure 110
Feature-by-Feature Comparison
Pricing & Access
| Feature | Scribeable | Freed AI |
|---|---|---|
| Published, self-serve pricingFreed publishes its plans: Starter $39/mo (up to 40 notes), Core $79/mo (unlimited), Premier $104-119/mo | ||
| Permanent free tierFreed offers a 7-day free trial with no card required; no ongoing free plan is listed on its pricing page | ||
| Coding (E/M, ICD-10, CPT) below $100/monthFreed lists E/M, ICD-10, and CPT coding on Premier at $104/mo billed annually or $119/mo monthly (its ICD-10 coding launched December 2025) |
Ownership & Capital
| Feature | Scribeable | Freed AI |
|---|---|---|
| Clinician-owned, direct-to-clinician accountFreed is also a direct-to-clinician product — on this dimension the two are alike | ||
| Zero outside capital (bootstrapped)Freed raised a $30M Series A led by Sequoia Capital (announced March 2025) |
Clinical Intelligence
| Feature | Scribeable | Freed AI |
|---|---|---|
| Deterministic clinical calculators (240, code-scored)Freed advertises "clinical decision support from 50+ trusted sources"; deterministic code-scored calculator validation is not stated | ||
| HCC V28 risk-adjustment codingFreed's own site does not mention HCC or risk-adjustment coding on any tier as of Jul 2026; its coding assistant lists E/M, ICD-10, and CPT | ||
| MIPS quality measures scored in the noteNot stated on getfreed.ai as of Jul 2026 | ||
| Verification surfaced to you (clarifying questions + flags before you sign)Freed's how-it-works page describes an internal automated double-check that "scans for AI hallucinations or inconsistencies" before delivery (as of Jul 2026); a verification pass surfaced to the clinician — questions asked to you, flagged statements you review before signing — is not stated |
Beyond the Note
| Feature | Scribeable | Freed AI |
|---|---|---|
| Orders queue extracted from the visitScribeable pulls the orders discussed in the visit into a review queue you approve before anything is placed; an orders queue is not stated on getfreed.ai as of Jul 2026 | ||
| Referral letters + ancillary documents (AVS, work/school, FMLA)Freed lists auto-generated clinical letters and visit summaries on its Premier tier ($104-119/mo); Scribeable generates referral letters, after-visit summaries, and work/school/FMLA support letters at Pro ($79/mo) | ||
| Chart-aware note generation (grounded in provided chart context)Freed added pre-visit prep in Dec 2025; grounding the generated note in provided chart context is not stated on getfreed.ai as of Jul 2026 | ||
| Real-time iOS + web sync with pocket quick-dictationScribeable syncs in-progress encounters across iOS and web in real time and adds quick-dictation from the phone; real-time cross-device sync is not stated on getfreed.ai as of Jul 2026 | ||
| Multi-patient Rounding ModeScribeable segments one continuous recording into separate notes per patient for inpatient rounding; a multi-patient rounding mode is not stated on getfreed.ai as of Jul 2026 |
Competitor facts on this page are sourced to each company's own public site and verified as of 2026-07-12; see page source for the full citation list. Competitor capabilities and pricing may change after that date.
Pricing Comparison
Freed AI
$39-119/month, published (7-day trial; no free tier listed)
Contact for pricing
Both companies publish pricing — credit to Freed for that. The difference is what's included: Scribeable's Pro tier at $79/month includes the coding engine and clinical calculators; Freed lists its coding (E/M, ICD-10, CPT) on its Premier tier at $104-119/month, with no mention of HCC risk adjustment.
Other AI scribes optimize for time to first draft. Scribeable optimizes for time to signed note, with a verification pass built in before you sign.
5.0 on the App Store120+
Clinicians on board
2,600+
Patient notes generated
Which Should You Choose?
Choose Freed AI if you...
- High-volume clinicians who want unlimited note generation at $79/month and don't need a coding engine
- Practices interested in Freed's separate AI front-desk product (listed from $149/month) alongside the scribe
- Clinicians already settled into Freed's workflow — it is a direct-to-clinician product with published pricing, like Scribeable
Frequently Asked Questions
Compare Other Alternatives
vs Dragon Copilot
Considering Microsoft Dragon Copilot, the product formerly sold as Nuance DAX? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and who each company answers to.
vs Nabla
Considering Nabla? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the "we don't train on your data" promise both companies make.
vs Abridge
Considering Abridge? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the platform.
Start Your 14-Day Free Trial — No Credit Card
Compare Scribeable to Freed AI on your own terms. Generate your first note in under 5 minutes.
Scribeable vs Freed AI - AI Medical Scribe Comparison
Considering Freed? Here is a factual look at how Scribeable differs. Freed publishes its pricing — credit where due — so this comparison is about what each subscription includes, and who each company answers to.
Why Physicians Switch from Freed AI
- No permanent free tier — Freed's pricing page lists a 7-day trial, then paid plans from $39/month
- Coding (E/M, ICD-10, CPT) sits on the Premier tier ($104-119/month) — not included at $39 or $79, per Freed's own pricing page; HCC risk adjustment is not mentioned at any tier
- VC-backed: a $30M Series A led by Sequoia Capital (March 2025) sets the growth expectations Freed answers to
Why Choose Scribeable Over Freed AI
- Permanent free tier — Freed's published plans start at $39/month after a 7-day trial
- Coding engine (ICD-10, HCC, E&M) included at Pro ($79/month) — Freed lists its coding (E/M, ICD-10, CPT) only on the $104-119/month Premier tier, with no mention of HCC risk adjustment
- 240 clinical calculators, code-scored and validated, inside every note
- A two-stage AI pipeline: a draft pass, then a separate verification pass that asks a clarification question instead of guessing
- Clinician-owned, portable account that moves with you across employers
- Zero outside capital — bootstrapped, no VC fund with a future exit to plan around
Credit Where Due — Then the Fine Print
Freed does what most competitors won't: it publishes its pricing. Starter is $39/month for up to 40 notes, Core is $79/month for unlimited notes, and Premier is $104-119/month. The fine print is what each price includes — on Freed's own pricing page, coding (E/M, ICD-10, CPT) appears only at the Premier tier, and HCC risk adjustment isn't mentioned at all. Scribeable's Pro tier at $79/month includes the coding engine, the HCC V28 crosswalk, and 240 clinical calculators. Same sticker, different contents.
The Note Is the Floor, Not the Ceiling
Freed's site advertises clinical decision support drawn from "50+ trusted sources." What it does not advertise is deterministic validation — calculators scored in code, not by a model's recollection. Scribeable runs 240 clinical calculators with code-scored validation inside every note, plus MIPS quality measures. If your documentation feeds risk-adjusted revenue or quality reporting, that layer is the difference between a transcript summary and a working clinical document.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Freed raised a $30M Series A led by Sequoia Capital in March 2025 — announced on Freed's own blog. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Feature Comparison: Scribeable vs Freed AI
Pricing & Access
| Feature | Scribeable | Freed AI |
|---|---|---|
| Published, self-serve pricing | Yes | Yes |
| Permanent free tier | Yes | No |
| Coding (E/M, ICD-10, CPT) below $100/month | Yes | No |
Ownership & Capital
| Feature | Scribeable | Freed AI |
|---|---|---|
| Clinician-owned, direct-to-clinician account | Yes | Yes |
| Zero outside capital (bootstrapped) | Yes | No |
Clinical Intelligence
| Feature | Scribeable | Freed AI |
|---|---|---|
| Deterministic clinical calculators (240, code-scored) | Yes | Partial |
| HCC V28 risk-adjustment coding | Yes | Partial |
| MIPS quality measures scored in the note | Yes | Partial |
| Verification surfaced to you (clarifying questions + flags before you sign) | Yes | Partial |
Beyond the Note
| Feature | Scribeable | Freed AI |
|---|---|---|
| Orders queue extracted from the visit | Yes | Partial |
| Referral letters + ancillary documents (AVS, work/school, FMLA) | Yes | Partial |
| Chart-aware note generation (grounded in provided chart context) | Yes | Partial |
| Real-time iOS + web sync with pocket quick-dictation | Yes | Partial |
| Multi-patient Rounding Mode | Yes | Partial |
Pricing Comparison
Scribeable: Free tier, then $39-79/month, published
Freed AI: $39-119/month, published (7-day trial; no free tier listed)
Both companies publish pricing — credit to Freed for that. The difference is what's included: Scribeable's Pro tier at $79/month includes the coding engine and clinical calculators; Freed lists its coding (E/M, ICD-10, CPT) on its Premier tier at $104-119/month, with no mention of HCC risk adjustment.
Which Should You Choose?
If you want a permanent free tier, deterministic calculators, and coding included at $79/month — from a bootstrapped vendor — that's Scribeable. If you want unlimited note generation at $79/month for documentation alone, or Freed's separate AI front-desk product alongside the scribe, Freed's Core or Front Desk plans may fit that workflow better.
Frequently Asked Questions
Does Freed publish its pricing?
Yes — one of the few competitors that does. Freed's pricing page lists Starter at $39/month (up to 40 notes), Core at $79/month (unlimited notes), and Premier at $104/month billed annually or $119/month monthly, with a 7-day free trial. Scribeable publishes $39/month (Lite) and $79/month (Pro), and adds a permanent free tier.
Does Freed include ICD-10 coding?
On its Premier tier — Freed lists E/M, ICD-10, and CPT coding at $104/month billed annually or $119/month monthly, as of July 2026 (its ICD-10 coding launched December 2025). HCC risk adjustment is not mentioned anywhere on Freed's site. Scribeable includes its coding engine (ICD-10, HCC V28 crosswalk, E&M support) at Pro, $79/month.
Is Freed VC-backed?
Yes. Freed announced a $30M Series A led by Sequoia Capital in March 2025 on its own blog. Scribeable has raised $0 in outside capital.
Can I run Scribeable and Freed side by side?
Yes. Scribeable's free tier and 14-day trial (no credit card) make it practical to run both on the same clinic days and compare the notes, the coding output, and the calculators before deciding.
Sources
Freed's published pricing: Starter $39/mo (up to 40 notes), Core $79/mo (unlimited notes), Premier $104/mo billed annually or $119/mo monthly (adds E/M, ICD-10, and CPT coding, EHR push integration, visit summaries, patient letters, and an AI assistant); 7-day free trial, no credit card; no permanent free tier listed. HCC / risk-adjustment coding is not mentioned.
Freed's December 2025 announcement describes ICD-10 code suggestions from the visit note and transcript, pre-visit prep, and auto-generated clinical letters; its features page markets "Optimized ICD-10, CPT, and E/M codes."
Freed advertises HIPAA compliance, SOC 2 Type II certification, clinical decision support from "50+ trusted sources," a separate Front Desk product starting at $149/month, and reports 26,000+ clinicians.
Freed raised a $30M Series A led by Sequoia Capital (announced March 2025).
Scribeable pricing: Lite $39/mo, Pro $79/mo.
Explore More
Discover how Scribeable can help your practice with AI-powered clinical documentation